Use of Complementary Health Approaches and Research Interests Among Older Adults in the COSMOS Trial.
A comprehensive survey of over 16,000 older adults revealed that complementary health approaches in older adults are mainstream, with nearly 60% reporting recent use. This prevalence data has significant implications for how clinicians should approach…
Trends in Cannabis Urine Drug Screen Testing in Colorado’s Largest Health System
This study analyzes cannabis urine drug screen trends in Colorado's largest health system. It highlights changes in testing rates and positivity over time. The findings reveal demographic factors influencing cannabis testing patterns.
What Do CBD Gummies Cost in 2026? A Practical Breakdown for Everyday Wellness
Understanding 2026 CBD gummies pricing is essential for patients seeking cannabinoid therapy. This practical cost breakdown highlights affordability challenges and dosing considerations. Clinicians can better counsel patients on sustainable CBD use with…
Understanding President Trump’s Executive Order on Medical Cannabis Rescheduling
The federal medical marijuana rescheduling update under President Trump’s executive order aims to remove barriers to research, prescribing, and insurance coverage. This change would enable standardized treatment guidelines and evidence-based dosing…
Federal move could ease restrictions on medical marijuana – KTLO
The federal move medical marijuana update signals potential easing of restrictions impacting clinical practice. This change could improve research capabilities and patient access. Healthcare providers should monitor these developments closely.
Some Medical Marijuana to Be Reclassified: Nationwide Legal Impact?
The federal medical marijuana reclassification clinical implications could change how cannabis-based medicines are prescribed and researched. This shift may improve access to FDA-approved cannabis medications. However, it does not legalize recreational…
Navigating Cannabis Legal Access Challenges and Federal Restrictions
Cannabis legal access challenges persist despite legalization in 24 states and DC. Federal scheduling creates barriers for clinical research and prescribing. These challenges impact clinicians and patients alike.
Trump Administration Updates Medical Marijuana Schedule III Reclassification
The medical marijuana schedule III reclassification update marks a significant federal policy shift. This change reduces research barriers and improves clinical access. It paves the way for expanded clinical trials and standardized prescribing.
Governor Calls Medical Marijuana Rescheduling an ‘Important Step’
Medical marijuana federal rescheduling impacts are significant for clinical research and prescribing authority. This policy change could reduce regulatory barriers and expand medical access. Clinicians should stay informed about these evolving federal…
What Marijuana Reclassification Means for Illinois – Axios Chicago
Marijuana reclassification Illinois could remove regulatory barriers that limit clinical research and banking services. This shift may accelerate evidence-based treatment protocols. Patients in Illinois could benefit from improved access to standardized…